GlassScriptPhysician profile
Carlos Campos
NPI 1376730747
$1,479,466.44
in general payments reported to CMS, 2019-2025
65 companies · $210K in 2025
The $210K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375K · 2020: $200K · 2021: $165K · 2022: $181K · 2023: $146K · 2024: $202K · 2025: $210K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $308K · Consulting Fee: $119K · Travel and Lodging: $113K · Food and Beverage: $18K · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $307,974.14 |
| Consulting Fee | $119,215.50 |
| Travel and Lodging | $112,863.52 |
| Food and Beverage | $17,926.98 |
| Education | $143.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $753,537.15 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $521,578.04 | 2019-2025 | Wegovy, Ozempic, Victoza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65,111.08 | 2019-2025 | Jardiance, Synjardy |
| Eli Lilly and Company | $55,144.07 | 2019-2025 | Mounjaro |
| Janssen Pharmaceuticals, INC | $54,322.79 | 2019-2023 | Xarelto |
| Janssen Scientific Affairs, LLC | $5,652.16 | 2019 | |
| Astellas Pharma US INC | $4,949.20 | 2022-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $4,304.17 | 2019-2025 | Airsupra |
| Abbott Laboratories | $2,528.22 | 2019-2024 | Afinion 2, Freestyle Libre 3, Proclaim |
| Abbvie INC. | $2,048.60 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Esperion Therapeutics, INC. | $1,103.23 | 2021-2025 | Nexletol |
| Corcept Therapeutics | $1,076.49 | 2020-2025 | Korlym |
| Mannkind Corporation | $838.93 | 2019-2025 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $704.40 | 2021-2025 | |
| Amarin Pharma, INC. | $482.75 | 2019-2022 |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $472.92 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $435.83 | 2022-2025 | Rexulti |
| Pfizer INC. | $398.96 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $391.66 | 2019-2022 | |
| Amgen INC. | $382.99 | 2019-2025 | Otezla, Repatha, Otezla |
| Bausch Health US, LLC | $345.71 | 2019-2025 | Aplenzin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $339.67 | 2020-2025 | Xifaxan |
| Medtronic, INC. | $311.37 | 2023-2025 | Venaseal, Kyphon Express II Kyphopak Tray, Minimed 780g |
| Glaxosmithkline, LLC. | $282.76 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Nevro Corp. | $191.00 | 2023-2024 | Senza |
| Novartis Pharmaceuticals Corporation | $181.56 | 2023-2025 | |
| Axsome Therapeutics, INC. | $150.83 | 2022-2025 | Auvelity, Sunosi |
| Dexcom, INC. | $145.34 | 2022-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $144.02 | 2020-2022 | |
| Intuitive Surgical, INC. | $135.00 | 2020 | |
| Phathom Pharmaceuticals, INC. | $113.09 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $97.92 | 2024 | Rezdiffra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.75 | 2025 | Caplyta |
| Ascensia Diabetes Care US INC. | $95.40 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $94.21 | 2023-2025 | Horizant, Horizant, Edarbi |
| Exact Sciences Corporation | $86.82 | 2024-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $83.91 | 2022-2025 | Recorlev |
| Merck Sharp & Dohme LLC | $83.44 | 2019-2021 | |
| Insulet Corporation | $81.30 | 2025 | Omnipod |
| Cequr Corporation | $75.41 | 2022-2024 | Cequr Simplicity |
| Recordati_rare_diseases_inc. | $75.19 | 2025 | Isturisa |
| Shield Therapeutics INC | $70.94 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $62.66 | 2022-2024 | Contrave, Onzetra Xsail |
| Vertex Pharmaceuticals Incorporated | $58.78 | 2025 | |
| Horizon Therapeutics Plc | $58.74 | 2020-2021 | |
| Globus Medical, INC. | $55.63 | 2025 | Senza |
| Echosens North America, INC. | $40.40 | 2025 | Fibroscan |
| Neurocrine Biosciences, INC. | $39.62 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $39.51 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $38.77 | 2019-2021 | |
| Painteq LLC | $36.09 | 2023-2024 | Painteq |
| Genentech, INC. | $28.72 | 2025 | |
| Soleno Therapeutics, INC. | $28.71 | 2025 | Vykat Xr |
| Idorsia Pharmaceuticals US INC | $27.12 | 2023 | Quviviq |
| Beta Bionics, INC. | $25.13 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Intra-Sana Laboratories | $23.77 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Valeritas, INC. | $23.47 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $21.34 | 2019 | |
| Averitas Pharma INC. | $21.27 | 2025 | Qutenza |
| Lundbeck LLC | $17.44 | 2022 | |
| Amneal Pharmaceuticals LLC | $16.79 | 2025 | Unithroid |
| Supernus Pharmaceuticals, INC. | $16.20 | 2021 | |
| Intuity Medical INC | $16.04 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Eisai INC. | $13.90 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Campos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.